Call Us: 1.800.873.5297

By

Risperdal: $2.5 Million Verdict for Plaintiff in Philadelphia State Court

Philadelphia Daily News reports that a Philadelphia jury has awarded a 20 year old autistic man, Austin Pledger, $2.5 million after he developed size 46 DD breasts (a condition referred to as gynecomastia) as a young teenager after using the antipsychotic drug Risperdal. In particular, the jury found that the manufacturer, Johnson & Johnson, failed […]

By

Johnson & Johnson Faces Trial in Risperdal® Breast-Development Case

Johnson & Johnson (J&J) will face trial to defend itself against claims that its antipsychotic drug, Risperdal®, causes gynecomastia, a condition that causes young boys and males to grow breasts. The lawsuit, brought in the Philadelphia Court of Common Pleas, involves a boy who ingested Risperdal®  at the age of 8 and subsequently suffered from […]

By

According to Expert in Philadelphia State Court Case, Actos Largest Bladder Cancer Risk for Plaintiff

Law 360 reports that setting aside a history of smoking and other risk factors, an expert witness told a jury in Philadelphia that the most significant contributing factor for the retired western Pennsylvania teacher, who was diagnosed with bladder cancer in 2008, was his long-term Actos use. University of Colorado oncologist and bladder cancer specialist […]

By

Transvaginal Mesh (MDL 2326) Update: Cases Against Boston Scientific Move Forward After First Two Bellwether Trials

Cases against Boston Scientific continue to move forward in the Multidistrict Litigation (In re: Boston Scientific Corp. Pelvic Repair System Products Liability Litigation, MDL 2326) before The Honorable Judge Joseph R. Goodwin in the United States District Court for the Southern District of West Virginia. According to the Court’s most recent Pretrial Order, new deadlines […]

By

TVM Lawsuit Update: Boston Scientific Ordered by Jury to Pay $26.7 Million In Damages

The Boston Journal reports that Boston Scientific, manufacturer of transvaginal mesh devices, has been ordered by a jury to pay four women a total of $26.7 million in compensatory damages. After an eight-day trial, the jury deliberated and found Boston Scientific liable for selling faulty transvaginal mesh devices. This was one of the first federal […]

By

Transvaginal Mesh Manufacturer Boston Scientific Sets Aside Nearly $1 Billion for Legal Expenses

In light of the ongoing lawsuits against Boston Scientific on behalf of women alleging severe injuries from their transvaginal mesh (TVM) devices, the 2006 acquisition of Guidant Corporation, and IRS tax issues, Boston Scientific has set aside nearly $1 Billion to pay legal expenses – as reported by the Boston Business Journal. According to the […]

By

$2 Million Verdict in Philadelphia State Court Actos® Case, Bloomberg Reports

Bloomberg reports that Takeda, the manufacturer of the diabetes medication Actos®, has been ordered by a Philadelphia jury to pay more than $2 Million in damages. The case was held in Philadelphia state court where jurors deliberated for more than five hours before finding that the manufacturers of Actos® failed to properly warn the plaintiff’s […]

By

Judge Allows Jurors in DePuy Pinnacle™ Trial to Hear About Other Cases in MDL

Law 360 reports that the jurors in the first federal DePuy Pinnacle™ bellwether case were allowed to hear about the 6,500 other cases pending in the MDL of plaintiffs alleging defects against the metal-on-metal hip implant manufacturer, thus lifting an earlier order barring such discussions. The Honorable Judge James Edgar “Ed” Kinkeade, who is presiding […]

By

DePuy Executive Questioned regarding Safety Studies for DePuy Pinnacle™ Hips

Reuters reports that an executive at Johnson & Johnson’s DePuy Orthopaedics Inc. unit has testified in the first DePuy Pinnacle™ bellwether regarding the company’s assessment of safety risks associated with its Pinnacle™ hip implants. Pamela Plouhar, the DePuy executive and worldwide vice president of clinical research, was questioned about the studies DePuy performed on these […]

By

Actos® Lawsuit Update: Judge Denies Takeda’s Motion to Overturn $9 Billion Jury Verdict in First MDL Actos® Trial

Bloomberg reports that The Honorable Judge Rebecca Doherty has ruled against Defendants Takeda Pharmaceutical Co. and Eli Lilly in their motion to overturn the $9 Billion verdict decided by a jury earlier this year. In particular, Judge Doherty ruled that jurors properly considered evidence showing that the officials for the manufacturers of Actos® were aware […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.